Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

New Antibody-Drug Conjugates on the Horizon

Date

20 Oct 2023

Session

AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Peter Schmid

Authors

P. Schmid

Author affiliations

  • Centre Of Experimental Cancer Medicine, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, EC1M 6BQ - London/GB

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Javier Cortés

Session: AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

Resources:

Webcast

Audience Q&A

Presenter: All Speakers

Session: AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

Resources:

Webcast

Concluding Remarks

Presenter: Javier Cortés

Session: AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.